Seems like whilever they hold the infusion business, the chance of going bankrupt is somewhat overplayed?
It appears the SP is lower than the option, so might as well just buy on-market again?
They are adament adapt is the pathway to CF+ and mathematically I guess that's correct as very high margin product and no growth in infusion business, and AI doesn't generate profit - only SP speculation. So I guess going all-in on adapt is the only choice. But we are not privy to the sales numbers and we have been criminally mislead in the recent past, so WTF do we do!?
Ann: Admedus launches rights issue, page-115
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.25 |
Change
-0.250(1.61%) |
Mkt cap ! $322.3M | |||
| Open | High | Low | Value | Volume |
| $15.50 | $15.50 | $14.80 | $140.4K | 9.315K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 297 | $15.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.25 | 1300 | 2 |
View Market Depth
| Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
| AVR (ASX) Chart |